MAPT and Alzheimer disease: These data collectively demonstrate the preclinical efficacy of a dendrimer-conjugated nSMase2 inhibitor to block the propagation of toxic hyperphosphorylated tau species in mice, representing an exciting new therapeutic strategy for AD.